Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: A surge in the use of semaglutide injection (Ozempic ® ) approved to treat type 2 diabetes (T2D) has led to a global supply shortage. We investigated contemporary user rates and clinical characteristics of semaglutide (Ozempic ® ) users in Denmark, and the extent of “off-label” prescribing for weight loss. Patients and Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic ® ) were included. We examined quarterly rates of new users and total user prevalences, using other glucagon-like peptide-1 receptor agonists and weight loss medications as comparison. We also investigated user characteristics including T2D, glucose control, comedications, and cardiorenal disease. Results: The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply. User prevalence increased to 91,626 users in Denmark in 2023. The proportion of semaglutide (Ozempic ® ) new users who had a record of T2D declined from 99% in 2018 to only 67% in 2022, increasing again to 87% in 2023. Among people with T2D who initiated semaglutide (Ozempic ® ) in 2023, 52% received antidiabetic polytherapy before initiation, 39% monotherapy, and 8% no antidiabetic therapy. Most T2D initiators had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol and 68% ≥ 53 mmol/mol despite use of antidiabetic medication, and 29% had established atherosclerotic cardiovascular disease or kidney disease. Conclusion: The use of semaglutide (Ozempic ® ) in Denmark has increased dramatically. Although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D. Conversely, most initiators with T2D had a clear medical indication for treatment intensification, and “off-label” use can only explain a minor part of the supply shortage. Keywords: drug utilization, epidemiology, anti-obesity drugs, glucose-lowering drugs, obesity, type 2 diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A surge in the use of GLP‐1RA has thus occurred in many countries over the last 3–4 years, even leading to periods of global supply shortage. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Population‐based studies from the United States (US) and Europe have documented substantial increases in anti‐obesity medication use during the last decade, 16 , 22 , 23 , 24 accelerating with the introduction of semaglutide and tirzepatide for weight loss. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A surge in the use of GLP‐1RA has thus occurred in many countries over the last 3–4 years, even leading to periods of global supply shortage. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Population‐based studies from the United States (US) and Europe have documented substantial increases in anti‐obesity medication use during the last decade, 16 , 22 , 23 , 24 accelerating with the introduction of semaglutide and tirzepatide for weight loss. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 9×
“Among people initiating semaglutide (Ozempic ® ) who had a record of T2D, we further described the number and type of prior antidiabetic medications used within the last year, the most recent HbA1c value measured within the last year, and the presence of established hospital-diagnosed atherosclerotic cardiovascular di…”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“10 In contrast, there is less clear evidence for an effectiveness of GLP-1RA on primary prevention of cardiovascular disease, both for T2D 42 and obesity, although there is some indication that GLP-1RAs may reduce cardiovascular outcomes in people with T2D and multiple cardiovascular risk factors,…”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“…disease, both for T2D 42 and obesity, although there is some indication that GLP-1RAs may reduce cardiovascular outcomes in people with T2D and multiple cardiovascular risk factors, 8 reflected in “Class IIb”, “Level C” recommendations in the most recent European Society of Cardiology guidelines.”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 3×
“3,22 Since 2015, numerous large cardiovascular outcome trials have shown that GLP-1RAs including semaglutide reduce cardiovascular and renal complications in high-risk T2D patients and confer organ-protective effects beyond lowering glucose.”
BackgroundObesity Stigma: Important Considerations for Public Health
Puhl, R. M., & Heuer, C. A. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.159491 · Cited by 1,917 · cited 1×
“33 14 Indeed, many primary care physicians report strongly increasing demands from their patients, and it is well-known that such pressure can lead to inappropriate prescribing patterns.”
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431 · cited 4×
“15,19 Codes used for medications, diagnoses, procedures, and laboratory tests are shown in Supplementary Table 1.”
BackgroundMethodInfluentialSelf-citationSchmidt, M., Schmidt, S. A. J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s179083 · Cited by 1,379 · cited 2×
“15,19 Codes used for medications, diagnoses, procedures, and laboratory tests are shown in Supplementary Table 1.”
Self-citationAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 2×
“5,16 Future routine clinical care studies should therefore follow the many new users of semaglutide and other incretin-based medications to investigate the adherence, safety, and effectiveness of these medications in a real-world setting.”
BackgroundLeBlanc, E. S., Patnode, C. D., Webber, E. M., Redmond, N., Rushkin, M., & O’Connor, E. A. (2018) · JAMA · doi:10.1001/jama.2018.7777 · Cited by 463
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272 · cited 1×
“Tirzepatide, a dual GIP/GLP-1 receptor agonist with even greater effectiveness on glycemia and weight loss than semaglutide, 23,24 received marketing authorization for diabetes treatment (Mounjaro ® ) in the European Union in 2022, 25 but is not yet available on the Danish market; the introduction…”
BackgroundTan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83 · cited 1×
“Tirzepatide, a dual GIP/GLP-1 receptor agonist with even greater effectiveness on glycemia and weight loss than semaglutide, 23,24 received marketing authorization for diabetes treatment (Mounjaro ® ) in the European Union in 2022, 25 but is not yet available on the Danish market; the introduction…”
BackgroundNargesi, A. A., Jeyashanmugaraja, G. P., Desai, N., Lipska, K., Krumholz, H., & Khera, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021084 · Cited by 61
Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Pottegård, A., Andersen, J. H., Søndergaard, J., Thomsen, R. W., & Vilsbøll, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14947 · Cited by 54 · cited 1×
“2 This accords with recommendations that most patients with T2D can receive high-quality care in general practice.”
BackgroundSelf-citationFunck, K. L., Knudsen, J. S., Hansen, T. K., Thomsen, R. W., & Grove, E. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14245 · Cited by 45
Self-citationThe future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44 · cited 1×
“4,5 Moreover, there is now randomized trial evidence for effectiveness of GLP-1RAs in secondary prevention of cardiovascular disease, 6 not only in patients with T2D, 7–9 but also in overweight or obese patients without diabetes.”
BackgroundPhysicians under Pressure: Evidence from Antibiotics Prescribing in England
Allen, T., Gyrd‐Hansen, D., Kristensen, S. R., Oxholm, A. S., Pedersen, L. B., & Pezzino, M. (2022) · Medical Decision Making · doi:10.1177/0272989x211069931 · Cited by 35 · cited 1×
“35 Finally, costs of semaglutide may play a role.”
Self-citationIannone, A., Natale, P., Palmer, S. C., Nicolucci, A., Rendina, M., Giorgino, F., Laviola, L., Di Leo, A., & Strippoli, G. F. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15138 · Cited by 27
Nicolaisen, S. K., Pedersen, L. H., Witte, D. R., Sørensen, H. T., & Thomsen, R. W. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110829 · Cited by 23 · cited 1×
“21 Study limitations include lack of data on the exact medical indication for physicians prescribing semaglutide (Ozempic ® ) or other medications, as only diagnoses made during hospital contacts are available for research purposes.”
BackgroundSelf-citationMannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16 · cited 1×
“10 In contrast, there is less clear evidence for an effectiveness of GLP-1RA on primary prevention of cardiovascular disease, both for T2D 42 and obesity, although there is some indication that GLP-1RAs may reduce cardiovascular outcomes in people with T2D and multiple cardiovascular risk factors,…”
BackgroundPharmacological treatment of obesity in adults in Norway 2004–2022
Ruiz, P. L., Karlstad, Ø., Nøkleby, K., Slåtsve, K., Gulseth, H. L., Meyer, H. E., Sveen, K. A., Qvigstad, E., & Furu, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15515 · Cited by 14 · cited 1×
“26 The authors reported a sharp increase in the use of semaglutide injection (Ozempic ® ) without reimbursement (i.e, “off-label” use) from 2021 to 2022, corroborating our findings in Denmark.”
Result
Research works printed but not linked: 1
- Iannone, 2023, Diabetes Obes Metab, 25, 2535, 10.1111/dom · doi:10.1111/dom
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Self-citationGLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16316 · Cited by 85
Self-citationGrauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00620-x · Cited by 79
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1455 · Cited by 61
Metadata
- Authors
- Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R.
- Affiliations
- Aarhus University (DK)
- University of Southern Denmark (DK)
- Danish Medicines Agency (DK)
- Corresponding author
- Thomsen, Reimar
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2024-04
- Volume
- Volume 16
- Pages
- 307-318
- ISSN
- 1179-1349 (ISSN-L)
- PMC
- PMC11057509
- OpenAlex
- W4395085097
- Cited by
- 60
- References
- 24
- Citations by year
- 2026: 25 · 2025: 29 · 2024: 6
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Novo Nordisk
- Sundhedsstyrelsen
- Diabetesforeningen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, Ozempic, off-label drug use, weight loss, type 2 diabetes, GLP-1 receptor agonists, drug use trends, drug shortages, glycemic control, HbA1c, atherosclerotic cardiovascular disease, kidney disease, Denmark, prescribing patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
